Searching for Hallandale Tirzepatide? Here's the UK Picture

What the SURMOUNT trials actually showed

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes across 72 weeks. At the 15mg dose, participants lost an average of around 20–21% of body weight. Those are meaningful numbers, but they come from a closely monitored clinical setting, using a product manufactured to defined pharmaceutical standards, with dose titration supervised by healthcare professionals.

That context matters more than it might sound. The results depend on a consistent, quality-assured product. Compounded tirzepatide, however it is labelled or packaged, is not manufactured to the same regulatory standards as Mounjaro, has not been through the MHRA's authorisation process, and is not legal to import for personal use under UK law. The results from SURMOUNT tell us what MHRA-approved tirzepatide can do, not what any formulation bearing the same active ingredient will do.

SURMOUNT-5, a head-to-head trial published in 2025, also found that tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks, which helped sharpen the clinical picture for prescribers choosing between the two options.

What 'compounded tirzepatide' from the US means for UK residents

In the United States, compounding pharmacies including Hallandale Health filled tirzepatide prescriptions during a period when the FDA placed Mounjaro on its shortage list. US compounding rules allowed this under specific conditions. Those conditions do not apply in the UK, and the FDA shortage designation has no bearing on UK supply or UK law.

A UK resident ordering compounded tirzepatide from a US compounder would be importing an unlicensed medicine. The MHRA has warned publicly about the risks of obtaining weight-loss medicines outside the regulated supply chain (including counterfeit and substandard products seized in large quantities) and advises patients to use only medicines prescribed and dispensed through legitimate UK channels. You can report suspect sellers at the MHRA's Yellow Card site.

One misconception worth setting aside gently: some readers assume that because a product contains the same molecule it must be equivalent. Pharmaceutical manufacturing is more complicated than that. Sterility, concentration accuracy and excipient safety all require validated processes, none of which a UK patient can assess from a product label.

Who qualifies for tirzepatide in the UK, and how it's accessed

NICE Technology Appraisal 1026 recommends tirzepatide for adults with a BMI of 35 or above and at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the threshold is 2.5 kg/m² lower. A BMI alone doesn't decide the outcome, the prescriber assesses the full clinical picture.

On the NHS, access is being phased in gradually and waiting lists remain common in many areas. Private treatment through a regulated online service is an alternative for people who meet the clinical criteria but don't want to wait. The licensed eligibility criteria for private prescription broadly mirror the medicine's UK marketing authorisation: adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. You can read more about how tirzepatide compares with other licensed options on our Mounjaro or tirzepatide guide.

Treatment begins at 2.5mg (a starting dose designed to let your body adjust before any increase) and is titrated upward by the prescriber, typically in four-week steps through the available strengths, and you can find details about one of those steps on our tirzepatide l page. For a broader overview of the treatment itself, the tirzepatide information page covers how it works, what to expect and the full licensed dosing path.

Cost, supply and what to check before proceeding

Understanding the cost of UK treatment is useful context before you commit. Eli Lilly raised Mounjaro's UK list price from September 2025; private prices have since ranged roughly £149–£375 per month depending on dose and provider, though these figures move and vary, and our tirzepatide 30 page gives more detail on what to expect at that end of the dosing range. Our Mounjaro cost guide explains what legitimate pricing typically includes (consultation, prescription, delivery and aftercare) and what to watch for when a price looks unusually low.

Before using any online pharmacy, check it on the GPhC register. A pharmacy registered with the GPhC has met standards for safe, legal dispensing. Sellers offering tirzepatide without requiring a prescription, or at prices far outside the market range, are a red flag regardless of how they are presented. Our team is available seven days a week if you have questions, the FAQs cover the most common ones, and you can always get in touch directly.

If you'd like to explore whether licensed tirzepatide treatment is right for you, you're welcome to speak to our prescribers, a free consultation is the starting point, with same-day clinical review by a GPhC-registered Independent Prescriber once your information is in.